Title

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.

Authors

Kris V Kowdley, Liver Care Network and Organ Care Research, Swedish Medical Center, 1124 Columbia Street, Suite 600, Seattle, WA, 98104, USAFollow
Vinay Sundaram
Christie Y Jeon
Kamran Qureshi
Nyan L Latt
Amandeep Sahota
Stephen Lott
Michael P Curry
Naoky Tsai
Nathorn Chaiyakunapruk
Yoori Lee
Jorg Petersen
Peter Buggisch

Document Type

Article

Publication Date

4-1-2017

Publication Title

Hepatology (Baltimore, Md.)

Keywords

Adult; Benzimidazoles; Biopsy, Needle; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Recurrence; Risk Assessment; Severity of Illness Index; Sofosbuvir; Time Factors; Treatment Outcome

Abstract

Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load

CONCLUSION: An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended. (Hepatology 2017;65:1094-1103).

Clinical Institute

Digestive Health

Department

Hepatology

Department

Infectious Diseases

Recommended Citation

Kowdley, Kris V; Sundaram, Vinay; Jeon, Christie Y; Qureshi, Kamran; Latt, Nyan L; Sahota, Amandeep; Lott, Stephen; Curry, Michael P; Tsai, Naoky; Chaiyakunapruk, Nathorn; Lee, Yoori; Petersen, Jorg; and Buggisch, Peter, "Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection." (2017). Articles, Abstracts, and Reports. 2355.
https://digitalcommons.providence.org/publications/2355